We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca is stepping up its case for its SGLT2 diabetes drug Farxiga with new numbersshowing it can cut the risk of serious cardiovascular complications in heart attack and heart failure patients.